- Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened pathology partnership service - Conference call begins at 4:30 p.m.
SAN DIEGO , May 1, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces
Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and
Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO , March 26, 2019 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO , March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types SAN DIEGO , March 18, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
SAN DIEGO , March 15, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
Proprietary platform enables local pathologists to participate in liquid biopsy testing with new capabilities to evaluate circulating tumor cells (CTCs) and expanded menu of biomarkers SAN DIEGO , March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid
Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer SAN DIEGO , March 4, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Saint John's and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company's Target Selector™ assay platform in patients with known or suspected brain metastases SAN DIEGO , Feb. 27, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
